Skip to main content

Chemotherapy-Induced Nausea and Vomiting (CINV)

10
Pipeline Programs
5
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
6
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Merck & Co.
EMENDApproved
fosaprepitant dimeglumine
Merck & Co.
intravenous2008
62K Part D

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
1
Fosaprepitant dimegluminePHASE_3
MSD
MSDIreland - Ballydine
4 programs
1
3
Comparator: fosaprepitant dimegluminePhase 31 trial
Fosaprepitant dimegluminePhase 31 trial
aprepitantPhase 31 trial
Fosaprepitant 150 mgPhase 11 trial
Active Trials
NCT01111851Completed16Est. Oct 2010
NCT00619359Completed2,322Est. Jun 2009
NCT01594749Completed1,015Est. Nov 2014
+1 more trials
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
4 programs
1
3
Comparator: fosaprepitant dimegluminePhase 3
Fosaprepitant dimegluminePhase 3
aprepitantPhase 3
Fosaprepitant 150 mgPhase 1
Helsinn
HelsinnIreland - Dublin
1 program
1
NetupitantPhase 21 trial
Active Trials
NCT03204279Completed67Est. Sep 2019
Heron Therapeutics
1 program
SUSTOLPHASE_41 trial
Active Trials
NCT05434663Unknown300Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heron TherapeuticsSUSTOL
MSDFosaprepitant dimeglumine
MSDaprepitant
MSDComparator: fosaprepitant dimeglumine
HelsinnNetupitant
MSDFosaprepitant 150 mg

Clinical Trials (6)

Total enrollment: 4,141 patients across 6 trials

NCT05434663Heron TherapeuticsSUSTOL

Safety Study of Repeat Doses of SUSTOL in Adults

Start: Jul 2022Est. completion: Oct 2025300 patients
Phase 4Unknown
NCT01594749MSDFosaprepitant dimeglumine

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Start: Sep 2012Est. completion: Nov 20141,015 patients
Phase 3Completed
NCT00952341MSDaprepitant

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Start: Aug 2009Est. completion: May 2010421 patients
Phase 3Completed
NCT00619359MSDComparator: fosaprepitant dimeglumine

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Start: Feb 2008Est. completion: Jun 20092,322 patients
Phase 3Completed
NCT03204279HelsinnNetupitant

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

Start: Aug 2017Est. completion: Sep 201967 patients
Phase 2Completed
NCT01111851MSDFosaprepitant 150 mg

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Start: Apr 2010Est. completion: Oct 201016 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.